Literature DB >> 4015487

Topical fluorouracil. Pharmacokinetics in normal rabbit eyes.

F E Fantes, D K Heuer, R K Parrish, N Sossi, M G Gressel.   

Abstract

Postoperative subconjunctival fluorouracil injections may be a useful adjunct to standard glaucoma filtering surgery in eyes that are at high risk of failure. Topical administration would be preferable to subconjunctival administration; however, there are no data on the ocular penetration of topically applied fluorouracil. Consequently, we investigated the pharmacokinetics of topically administered fluorouracil labeled with carbon 14 in normal rabbit eyes. One drop (approximately 2.4 mg) of fluorouracil resulted in the following concentrations at 0.5 and six hours, respectively: 17.3 and 0.9 micrograms/g of conjunctiva; 24.3 and 1.3 micrograms/g of cornea; 14.6 and 0.2 micrograms/mL of aqueous; 0.8 and 0.5 microgram/g of lens; 1.1 and 0.3 microgram/g of vitreous; and 0.2 and less than 0.1 microgram/mL of serum. Three drops (approximately 7.2 mg) of fluorouracil resulted in the following concentrations at 0.5 and eight hours, respectively: 589.8 and 1.3 micrograms/g of conjunctiva; 502.9 and 1.8 micrograms/g of cornea; 199.6 and 0.8 micrograms/mL of aqueous; 6.2 and 0.5 micrograms/g of lens; 6.8 and 0.5 micrograms/g of vitreous; and 1.3 and 0.2 microgram/mL of serum. Since a fluorouracil concentration of 0.2 microgram/mL inhibits rabbit conjunctival fibroblast proliferation in cell culture by 50%, these data suggest that topically applied fluorouracil achieves sufficient levels in the ocular compartments and tissues to have potential therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015487     DOI: 10.1001/archopht.1985.01050070079034

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  6 in total

Review 1.  Ocular drug delivery. Pharmacokinetic considerations.

Authors:  R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

2.  Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats.

Authors:  Youn-Shen Bee; Shwu-Jiuan Sheu; Yi-Ling Ma; Hsiu-Chen Lin; Wen-Tsang Weng; Hsiao-Mei Kuo; Huei-Chun Hsu; Chia-Hua Tang; Jau-Cheng Liou; Ming-Hong Tai
Journal:  Mol Vis       Date:  2010-04-28       Impact factor: 2.367

Review 3.  The clinical applications of fluorouracil in ophthalmic practice.

Authors:  Lekha M Abraham; Dinesh Selva; Robert Casson; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Pharmacokinetics of a 5-fluorouracil liposomal delivery system.

Authors:  S T Simmons; M B Sherwood; D A Nichols; R B Penne; T Sery; G L Spaeth
Journal:  Br J Ophthalmol       Date:  1988-09       Impact factor: 4.638

5.  Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid.

Authors:  R J de Keizer; D de Wolff-Rouendaal; J L van Delft
Journal:  Doc Ophthalmol       Date:  1986-12-30       Impact factor: 2.379

6.  Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.

Authors:  Shwu-Jiuan Sheu; Youn-Shen Bee; Yi-Ling Ma; Guei-Sheung Liu; Hsiu-Chen Lin; Tse-Liang Yeh; Jau-Chen Liou; Ming-Hong Tai
Journal:  Mol Vis       Date:  2009-09-18       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.